On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
Reuters on MSN11d
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's ...
On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of ...
In a report released today, Peter Verdult from Citi maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00. The company’s shares closed last Tuesday at $114.50.
Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback